Sleep Apnea Device Receives FDA Approval - Summary - MDSpire

Sleep Apnea Device Receives FDA Approval

Randomized trial data support the approval, with sustained improvements in apnea severity observed.

  • By

  • Kathryn Wighton

  • March 19, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of the aura6000 System for treating obstructive sleep apnea in patients who have not responded to first-line therapies.

Key Findings:
  • 65% of patients met responder criteria at 12 months.
  • Median apnea-hypopnea index decreased from 34.3 to 11.0 events per hour over 13 months.
  • 69% of treated patients achieved at least a 25% reduction in oxygen desaturation index.
Interpretation:

The aura6000 System represents a significant advancement in the treatment of obstructive sleep apnea, particularly for patients who are not candidates for traditional therapies.

Limitations:
  • The study population included patients with predicted risk of complete concentric collapse, which may not represent all obstructive sleep apnea patients.
  • Long-term efficacy and safety beyond the trial period remain to be fully established.
Conclusion:

The aura6000 System is the first hypoglossal nerve stimulation device approved in the US without contraindications related to complete concentric collapse, with promising results from clinical trials.

Original Source(s)

Sleep Apnea Device Receives FDA Approval

  • by Kathryn Wighton

  • March 19, 2026

Related Content

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Side Effects: Medicine's Blind Spot

Medicine is having a week: new insights on nutrition training, a rethink of “spring fatigue,” evidence that avocados may support artery health, and an AI that can spot rare hormone tumors from a hand photo

Infections Lead Thoracic CT Findings in SLE

Researchers characterize spectrum of pulmonary and extrathoracic involvement in systemic lupus erythematosus.